IGC Pharma Presents Genetic Toxicology Safety Data on API in IGC-AD1, at the 2025 Genetic Toxicology Association Meeting
Part of the FDA's battery of safety requirements is to show that APIs are safe for human consumption, including that they do not alter or mutate genes. IGC completed this requirement and is now able to show that the APIs in IGC-AD1 are safe and do not alter genes.
'This is an important milestone, as we prepare the drug for larger trials and eventual commercialization. The geno-tox data was presented at the annual conference on Genetic Toxicology held in Delaware, on May 8, 2025.' Said Ram Mukunda CEO of IGC Pharma.
This GLP-compliant study, conducted by an independent lab in Canada, evaluated the API's mutagenic potential using the Bacterial Reverse Mutation Test (commonly known as the Ames test), as part of a broader genetic toxicology battery. The study assessed multiple bacterial strains (Salmonella typhimurium TA1535, TA1537, TA98, TA100 and Escherichia coli WP2 trp uvrA) both in the presence (+S9) and absence (-S9) of an exogenous mammalian metabolic activation system, as per OECD Guideline 471 and ICH S2(R1) recommendations.
At various concentrations ranging from 1.6 to 5000 µg/plate, no evidence of mutagenicity was observed at any dose level. Across all strains and experimental conditions, Fold Response values remained below 2-the established threshold for mutagenic activity. Revertant colony counts remained within the range of the negative controls and substantially lower than the positive controls, confirming assay validity. Additionally, statistical analysis using Dunnett's test showed no significant dose-related increases (p > 0.05), reinforcing the conclusion that the API does not induce gene mutations under the tested conditions.
To access the full poster or learn more about IGC Pharma's ongoing research, please visit the LINK.
About IGC Pharma (dba IGC):
IGC Pharma (NYSE American: IGC) is a clinical-stage biotechnology company leveraging AI to develop innovative treatments for Alzheimer's and metabolic disorders. Our lead asset, IGC-AD1, is a cannabinoid-based therapy currently in a Phase 2 trial ( CALMA ) for agitation in Alzheimer's dementia. Our pipeline includes TGR-63, targeting amyloid plaques, and early-stage programs focused on neurodegeneration, tau proteins, and metabolic dysfunctions. We integrate AI to accelerate drug discovery, optimize clinical trials, and enhance patient targeting. With 30 patent filings and a commitment to innovation, IGC Pharma is advancing breakthrough therapies.
Forward-Looking Statements:
This press release contains forward-looking statements. These forward-looking statements are based largely on IGC Pharma's expectations and are subject to several risks and uncertainties, certain of which are beyond IGC Pharma's control. Actual results could differ materially from these forward-looking statements as a result of, among other factors, the Company's failure or inability to commercialize one or more of the Company's products or technologies, including the products or formulations described in this release, or failure to obtain regulatory approval for the products or formulations, where required, or government regulations affecting AI or the AI algorithms not working as intended or producing accurate predictions; general economic conditions that are less favorable than expected; the FDA's general position regarding cannabis- and hemp-based products; and other factors, many of which are discussed in IGC Pharma's U.S. Securities and Exchange Commission ('SEC') filings. IGC incorporates by reference its Annual Report on Form 10-K filed with the SEC on June 24, 2024, and on Form 10-Qs filed with the SEC on August 7, 2024, November 12, 2024, and February 14, 2025, as if fully incorporated and restated herein. Considering these risks and uncertainties, there can be no assurance that the forward-looking information contained in this release will occur.
Contact Information
Rosalyn Christian
IMS Investor Relations
[email protected]
(203) 972-9200
SOURCE: IGC Pharma, Inc.
press release
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
16 minutes ago
- Yahoo
On Holding AG (ONON): I'm Double Minded About The Stock, Says Jim Cramer
We recently published . On Holding AG (NYSE:ONON) is one of the stocks Jim Cramer recently discussed. On Holding AG (NYSE:ONON) is an athletic apparel retailer whose stock has lost 18% year-to-date on the back of investor concerns about the broader retail industry. The shares dipped by 8% last week after Tapestry warned that it expected tariffs to hit its profits. Cramer discussed the movement in On Holding AG (NYSE:ONON)'s shares and warned that he might have been too bullish about the firm previously. Here is what he said: 'A lot of the apparel stocks are down off of Tapestry. I've got to tell you, I mean Ralph Lauren is too. But the one that I've been watching is On Holding. I thought On Holding had a good quarter. I've been either disabused of that notion or perhaps I've been too bullish about these guys. If ONON is not doing as well, then you have to start thinking about Nike again. ' Mbuso Sydwell Nkosi/ Here are his previous comments about On Holding AG (NYSE:ONON): 'One of my favorite companies is On Holding. Now it has been stuck in a holding pattern. They reported very good numbers today, the stock was initially up seven, now it's down. There's a substantial short position, the shorts have been winning in this battle. I think Roger Federer in the end wins. But it is a very contested group.' While we acknowledge the potential of ONON as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the . READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now. Disclosure: None. This article is originally published at Insider Monkey.
Yahoo
16 minutes ago
- Yahoo
Tech Stocks Are Under Pressure. Why Some Wall Street Analysts Say That May Not Last
Tech stocks are having a rough day, extending their recent slump amid a sector rotation away from big tech leaders. The Nasdaq lost close to 1% in recent trading, and the S&P 500 slid 0.4% as tech sector losses weighed on the indexes. The Dow Jones Industrial Average was little changed as retail and consumer defensive names gained, while Amazon (AMZN), Apple (AAPL), and Nvidia (NVDA) ranked among its weakest performers as all of the "Magnificent Seven" stocks declined. Caution ahead of a speech from Federal Reserve Chair Jerome Powell on Friday, uncertainty about policy changes from the Trump administration, and worries about returns from AI spending have all added to pressures on the sector. However, some Wall Street analysts said they don't expect that to last long. "While some near-term tech volatility is not surprising given the run-up in valuations, we advise investors against becoming overly defensive," UBS said Wednesday. "While we think some caution may be warranted in the more cyclical parts of tech, we remain confident in the broader AI sector's long-term growth and resilience. We recommend investors seek balanced exposure across the AI value chain (infrastructure, semis, and applications), with a preference for laggards offering a more attractive risk-reward balance," UBS said. "We view tech sell-offs like yesterday as opportunities," bullish analysts at Wedbush told clients in a note Wednesday, suggesting the slump could be short-lived, and pointed to earnings from AI chipmaker Nvidia next week as a potential positive catalyst. "When Nvidia reports earnings next week on August 27th the tech world and Wall Street will be listening closely," they said, adding that they believe the "tech bull cycle will be well intact at least for another 2-3 years given the trillions being spent on AI." Read the original article on Investopedia Sign in to access your portfolio
Yahoo
16 minutes ago
- Yahoo
Jim Cramer Says Reports Of Apple Inc. (AAPL)'s 'Death' Are Overblown
We recently published . Apple Inc. (NASDAQ:AAPL) is one of the stocks Jim Cramer recently discussed. Giuseppe Costantino/ Apple Inc. (NASDAQ:AAPL)'s shares have reversed tack recently as the firm appears to have smoothed over its friction with the Trump administration. The firm announced a $100 billion additional investment in the US earlier this month, and the shares have gained 13.8% since then. Cramer discussed Apple Inc. (NASDAQ:AAPL)'s shares adding 30 dollars to their value in ten days: 'Well we've got a lot of exciting things that people are talking about. About the release perhaps of new AI powered products. Uh, smart home push, including robots. Life like version of Siri, well that would certainly be helpful. Smart speaker with display and home security camera. I don't know, home security is something that people want but the main thing here is that if we get robots and they're not from Musk, they're from Apple, I think we'd be very interested in that. While we acknowledge the potential of AAPL as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the . READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now. Disclosure: None. This article is originally published at Insider Monkey.
